New hope for Tough-to-Treat lung cancer
NCT ID NCT05773092
Summary
This study is testing whether adding a drug called S-1 to a standard lung cancer medication (osimertinib) can help control cancer that has started growing again. It is for 30 adults with a specific type of advanced lung cancer (EGFR mutant NSCLC) that has become resistant to osimertinib. The main goal is to see if the combination can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Singapore
Singapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.